| __timestamp | Bausch Health Companies Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 461543000 |
| Thursday, January 1, 2015 | 582800000 | 634806000 |
| Friday, January 1, 2016 | 455000000 | 661905000 |
| Sunday, January 1, 2017 | 366000000 | 610753000 |
| Monday, January 1, 2018 | 414000000 | 696328000 |
| Tuesday, January 1, 2019 | 471000000 | 715007000 |
| Wednesday, January 1, 2020 | 452000000 | 628116000 |
| Friday, January 1, 2021 | 465000000 | 628793000 |
| Saturday, January 1, 2022 | 529000000 | 649606000 |
| Sunday, January 1, 2023 | 604000000 | 746773000 |
| Monday, January 1, 2024 | 747184000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, strategic investment in research and development (R&D) is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc. have demonstrated contrasting approaches to R&D spending. BioMarin has consistently outpaced Bausch Health, with its R&D expenses growing by approximately 62% from 2014 to 2023. In 2023, BioMarin's R&D spending reached a peak, marking a 20% increase from the previous year. Meanwhile, Bausch Health's R&D investment, although showing a steady increase, grew by about 145% over the same period, with a notable surge in 2023. This divergence highlights BioMarin's aggressive pursuit of innovation, while Bausch Health appears to be catching up. These trends underscore the importance of R&D in driving pharmaceutical advancements and maintaining competitive advantage.
Comparing Innovation Spending: AbbVie Inc. and Bausch Health Companies Inc.
Novartis AG vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Gilead Sciences, Inc. vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
BioMarin Pharmaceutical Inc. or Apellis Pharmaceuticals, Inc.: Who Invests More in Innovation?
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Strategic Focus on R&D Spending
Gross Profit Analysis: Comparing BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and Bausch Health Companies Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Bausch Health Companies Inc.